Miguel G Garber et al., J Cell Sci Ther 2014, 5:4
http://dx.doi.org/10.4172/2157-7013.S1.028

OMICS Group Conferences
Accelerating Scientific Discovery

4th World Congress on
Cell Science & Stem Cell Research
June 24-26, 2014 Valencia Conference Centre, Valencia, Spain

Use of the stem cell mobilizer SE2® as part of conventional treatment on ankle injuries to expedite recovery in professional soccer players

Miguel G Garber[1], Mazzoni P[2], Drapeau C[2], Gutierrez Viñuales J[3] and Nazir C[1]
[1]Clinica Quirurgica Quantum, Spain
[2]Stemtech International, USA
[3]Rayo Majadahonda Football Club, Spain

Ankle injuries are the most common injuries for soccer players. The number of peripheral blood stem cells (PBSC) is a key parameter in the speed and extent of recovery after an injury. In an animal study, the stem cell mobilizer StemEnhance® accelerated muscle repair after induced muscle injury. Both StemEnhance® and its advanced formula SE2® have been shown to trigger a significant increase in the number of PBSC. The purpose of this study is to determine whether SE2® could enhance the effectiveness of conventional treatment for sport ankle injuries. Twelve male professional soccer players were randomly assigned to either experimental (SE2®) or control group. Both groups received conventional treatment. The experimental group received 12 capsules of SE2® daily for a full month. Patients were evaluated by the team's doctor with soft tissue sonogram at days 1, 7, 14 and 21. The Karlsson and Peterson Scoring System for Ankle function and Tegner activity level scale were taken every other day. The median severity of acute ankle injuries was similar in both groups. The participants were pair matched within the limits of the study. The SE2® group experienced a significantly greater reduction in pain, range of motion and joint stability compared with the control group. Recovery time was on average 17 days for the SE2® group versus 21 days for the control group. In conclusion, the use the stem cell mobilizer SE2® in conjunction with conventional treatment reduced the recovery time from acute ankle injuries in male football players.

Biography

Miguel G Garber currently is the Chief Science Director at Clinica Quirurgica Quantum. He has over 27 years experience in Internal medicine and cardiology, with expertise in regenerative medicine, training and education, research, product development and senior management. He has more than 10 years working with Stem Cell, including building and managing the stem cell evaluation, explore and developing stem cell therapies for cardiomyopathies, osteoarthritis and regenerative medicine at Stem cell Therapeutics Department of American Medical Information Group and Clinica Quirurgica Quantum. He is currently serving as Medical Director of Clinica Quantum and Clinical Director of regenerative Medicine department at Clinica Quantum, ongoing of several investigative research involved *Stem Cells* application (ASC) and Drug stimulating stem cells (Aphanizomenón Flos Aquae).

mggarber@gmail.com